IP Library Granted Patent US 7,196,086
Granted Patent B2
US 7,196,086 · App. 10/832,109 · Granted Mar 27, 2007

Substituted dihydroquinazolines

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,196,086
App. No.
10/832,109
Granted
Mar 27, 2007
Kind
B2
Abstract

The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.

Claims (59)

1. A compound of the formula

in which

Ar represents aryl which may be substituted by 1 to 3 substituents, where the substituents are selected independently of one another from the group consisting of alkyl, alkoxy, formyl, carboxyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl, amino, alkylamino, aminocarbonyl and nitro,

where alkyl may be substituted by 1 to 3 substituents, where the substituents are selected independently of one another from the group consisting of halogen, amino, alkylamino, hydroxyl and aryl,

R 1 represents hydrogen, amino, alkyl, alkoxy, alkylamino, alkylthio, cyano, halogen, nitro or trifluoromethyl,

R 2 represents hydrogen, alkyl, alkoxy, alkylthio, cyano, halogen, nitro or trifluoromethyl,

R 3 represents amino, alkyl, alkoxy, alkylamino, alkylthio, cyano, halogen, nitro, trifluoromethyl, alkylsulphonyl or alkylaminosulphonyl

R 4 represents hydrogen or alkyl,

R 5 represents hydrogen or alkyl

or

the radicals R 4 and R 5 are attached to carbon atoms directly opposing each other in the piperazine ring and form a methylene bridge which is optionally substituted by 1 or 2 methyl groups,

R 6 represents alkyl, alkoxy, alkylthio, formyl, carboxyl, aminocarbonyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl or nitro,

R 7 represents hydrogen, alkyl, alkoxy, alkylthio, formyl, carboxyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl or nitro

and

R 8 represents hydrogen, alkyl, alkoxy, alkylthio, formyl, carboxyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl or nitro,

or a salt, solvate, or solvate of a salt thereof.

2. A compound according to claim 1 , wherein

Ar represents phenyl which may be substituted by 1 to 3 substituents, where the substituents are selected independently of one another from the group consisting of C 1 –C 6 -alkyl, C 1 –C 6 -alkoxy, carboxyl, C 1 –C 6 -alkylcarbonyl, C 1 –C 6 -alkoxycarbonyl, trifluoromethyl, fluorine, chlorine, bromine, cyano, hydroxyl, amino, C 1 –C 6 -alkylamino and nitro,

R 1 represents hydrogen, C 1 –C 3 -alkyl, C 1 –C 3 -alkoxy, C 1 –C 3 -alkylthio, fluorine or chlorine,

R 2 represents hydrogen, C 1 –C 3 -alkyl, C 1 –C 3 -alkoxy, C 1 –C 3 -alkylthio, fluorine or chlorine,

R 3 represents C 1 –C 4 -alkyl, cyano, fluorine, chlorine, nitro, trifluoromethyl or C 1 –C 3 -alkylsulphonyl,

R 4 represents hydrogen or methyl,

R 5 represents hydrogen,

R 6 represents C 1 –C 3 -alkyl, C 1 –C 3 -alkoxy, carboxyl, aminocarbonyl, trifluoromethyl, fluorine, chlorine, cyano, hydroxyl or nitro,

R 7 represents hydrogen, C 1 –C 3 -alkyl, C 1 –C 3 -alkoxy, fluorine, chlorine, cyano or hydroxyl

and

R 8 represents hydrogen, C 1 –C 3 -alkyl, C 1 –C 3 -alkoxy, fluorine, chlorine, cyano or hydroxyl.

3. A compound according to claim 1 wherein

Ar represents phenyl which may be substituted by 1 or 2 substituents, where the substituents are selected independently of one another from the group consisting of methyl, methoxy, fluorine and chlorine,

R 1 represents hydrogen, methyl, methoxy, methylthio, fluorine or chlorine,

R 2 represents hydrogen,

R 3 represents methyl, isopropyl, tert-butyl, cyano, fluorine, chlorine, nitro or trifluoromethyl,

R 4 represents hydrogen,

R 5 represents hydrogen,

R 6 represents aminocarbonyl, fluorine, chlorine, cyano or hydroxyl,

R 7 represents hydrogen

and

R 8 represents hydrogen, fluorine or chlorine.

4. A compound according to claim 1 , wherein R 1 represents hydrogen, methyl, methoxy or fluorine.

5. A compound according to claim 1 , wherein R 1 represents methoxy.

6. A compound according to claim 1 , wherein R 1 is attached to the phenyl ring via the position ortho to the point of attachment of the phenyl ring.

7. A compound according to claim 1 , wherein R 2 represents hydrogen.

8. A compound according to claim 1 , wherein R 3 represents trifluoromethyl, chlorine, methyl, isopropyl or tert-butyl.

9. A compound according to claim 1 , wherein R 3 represents trifluoromethyl, chlorine or methyl.

10. A compound according to claim 1 , wherein R 1 is attached to the phenyl ring via the position ortho to the point of attachment of the phenyl ring and R 3 is attached to the phenyl ring via the position meta to the point of attachment of the phenyl ring, which position is opposite to that of R 1 .

11. A compound according to claim 1 , wherein R 4 and R 5 represent hydrogen.

12. A compound according to claim 1 , wherein R 6 represents fluorine.

13. A compound according to claim 1 , wherein R 7 represents hydrogen.

14. A compound according to claim 1 , wherein R 8 represents hydrogen, methyl or fluorine.

15. A compound according to claim 1 , wherein Ar represents phenyl which may be substituted by 1 or 2 substituents, where the substituents are selected independently of one another from the group consisting of methyl, methoxy, fluorine and chlorine.

16. A process for preparing a compound of the formula (I) according to claim 1 , wherein a compound of the formula

in which

Ar, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined in claim 1

and

R 9 represents alkyl selected from the group consisting of methyl, ethyl, and tert-butyl,

is reacted with a base or an acid.

17. A medicament comprising a compound according to claim 1 in combination with an inert non-toxic pharmaceutically acceptable auxiliary.

18. A method for treating infection by Herpes viridae in humans and animals by administering an antivirally effective amount of at least one compound according to claim 1 , or a medicament according to claim 17 .

19. The method according to claim 18 , wherein the Heprpes viridae is selected form the group consisting of cytomegalovirus (CMV) and human cytomegalovirus (HCMV) or another representative of the group of the Herpes viridae.

Assignments (5)
CHANGE OF NAME Recorded Sep 9, 2021
From: AIC246 GMBH & CO. KG
To: AIC246 AG & CO. KG
Reel/Frame 057447/0605 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2021
From: AICURIS ANTI-INFECTIVE CURES GMBH
To: AIC246 GMBH & CO. KG
Reel/Frame 057371/0159 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2017
From: AICURIS GMBH & CO. KG
To: AICURIS ANTI-INFECTIVE CURES GMBH
Reel/Frame 044694/0085 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2008
From: BAYER HEALTHCARE AG
To: AICURIS GMBH & CO. KG
Reel/Frame 021230/0843 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2004
From: WUNBERG, TOBIAS; BAUMEISTER, JUDITH; BETZ, ULRICH; JESKE, MARIO; LAMPE, THOMAS; NIKOLIC, SUSANNE; REEFSCHLAGER, JURGEN; SCHOHE-LOOP, RUDOLF; SUBMEIER, FRANK; ZIMMERMANN, HOLGER; GROSSER, ROLF; HENNINGER, KERSTIN; HEWLETT, GUY; KELDENICH, JORG; LANG, DIETER; NELL, PETER
To: BAYER HEALTHCARE AG
Reel/Frame 015421/0507 →